PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT00174382
- Locations
- 🇨🇦
Pfizer Investigational Site, Regina, Saskatchewan, Canada
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children
Phase 1
Completed
- Conditions
- Neutropenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00174473
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00174343
- Locations
- 🇫🇷
Pfizer Investigational Site, St. Cloud, France
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00174369
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00174434
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
Phase 3
Completed
- Conditions
- Growth Hormone DeficiencyGrowth Retardation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00174278
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Phase 2
Completed
- Conditions
- Attention Deficit Disorder With Hyperactivity
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT00174226
- Locations
- 🇺🇸
Pfizer Investigational Site, Woodstock, Vermont, United States
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
Phase 3
Completed
- Conditions
- Growth Disorder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00174421
Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age
Phase 3
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00174408
Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Phase 4
Completed
- Conditions
- Osteoarthritis, Hip
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00174317
- Locations
- 🇬🇧
Pfizer Investigational Site, Wigan, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath